Usually, MSH6 mutations account for about 7–10% of the pathogenic mutations in LS and in our study, the absence of mutations may be due to features of the group of patients under study (colorectal cancer patients with a first cancer diagnosis under the age of 45 years in average) and/or due to our small sample size. Here, MSH6 is linked to colorectal cancer.